HOUGEN ELIZABETH L - 16 Mar 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Mar 2026, 17:19:18 UTC
Prior SEC filing
02 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Patrick R. O'Neil, attorney-in-fact For: Elizabeth L. Hougen

Key filing fact

HOUGEN ELIZABETH L filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 18 Mar 2026.

Key facts

  • This page summarizes HOUGEN ELIZABETH L's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
  • 11 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 17:19.

Change

  • Previous filing in this sequence was filed on 02 Feb 2026.
  • Current net transaction value: -$16,313,676.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001074773 Primary reporting owner

HOUGEN ELIZABETH L

Relationship
EVP, Finance & CFO
Address
2855 GAZELLE COURT, CARLSBAD
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Elizabeth L. Hougen
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares
+60,299
Change %
+45%
Price
$60.89*
Shares after
193,180
Date
16 Mar 2026
Ownership
Direct
IONS transaction

Common Stock

Options Exercise

Transaction value
Shares
+61,041
Change %
+32%
Price
$56.78*
Shares after
254,221
Date
16 Mar 2026
Ownership
Direct
IONS transaction

Common Stock

Options Exercise

Transaction value
Shares
+33,118
Change %
+13%
Price
$32.60*
Shares after
287,339
Date
16 Mar 2026
Ownership
Direct
IONS transaction

Common Stock

Options Exercise

Transaction value
Shares
+20,541
Change %
+7.1%
Price
$37.58*
Shares after
307,880
Date
16 Mar 2026
Ownership
Direct
IONS transaction

Common Stock

Sale

Transaction value
$14,882,113
Shares
-205,608
Change %
-67%
Price
$72.38
Shares after
102,272
Date
16 Mar 2026
Ownership
Direct
Footnotes
F1, F2
IONS transaction

Common Stock

Sale

Transaction value
$686,902
Shares
-9,440
Change %
-9.2%
Price
$72.76
Shares after
92,832
Date
16 Mar 2026
Ownership
Direct
Footnotes
F1, F3
IONS transaction

Common Stock

Sale

Transaction value
$744,662
Shares
-10,172
Change %
-11%
Price
$73.21
Shares after
82,660
Date
17 Mar 2026
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-33,118
Change %
-100%
Price
$0.000000*
Shares after
0
Date
16 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
33,118
Exercise price
$32.60
IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-20,541
Change %
-79%
Price
$0.000000*
Shares after
5,405
Date
16 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,541
Exercise price
$37.58
IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-61,041
Change %
-100%
Price
$0.000000*
Shares after
0
Date
16 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
61,041
Exercise price
$56.78
IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-60,299
Change %
-100%
Price
$0.000000*
Shares after
0
Date
16 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,299
Exercise price
$60.89
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .